AIH Response to FDA
The American Institute of Homeopathy’s public statement regarding the FDA’s proposed regulation of homeopathy
The American Institute of Homeopathy (AIH) in concert with the American Association of Homeopathic Pharmacists (AAHP) shares the Food and Drug Administration’s (FDA) commitment to protecting public health and supports their plan to take quick action against illegal or unsafe homeopathic medicines in the United States’ marketplace. The AIH has encouraged the FDA to take this action in comments made at their regulatory body workshop in April 2015 and we are confident that the current Compliance Policy Guide continues to provide the FDA with ample opportunity to take such action.
The AIH also notes that the draft guidance will not materially affect most homeopathic drug products available in the United States. These products have a wide margin of safety when manufactured according to current Good Manufacturing Practices (GMPs). The AIH recognizes that the current Compliance Policy Guide 400.400 will remain in effect.
The AIH looks forward to working with the FDA as well as the many other homeopathic organizations, including the AAHP, in providing guidance on their new guidelines during the open comment period. As always, the AIH remains committed to ensuring that consumers have access to natural, safe, homeopathic medicines in the United States and throughout the world.
Revised January 9, 2018